Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,754 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Catastrophization
Interventions: Cognitive Therapy, Routine Care; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Squamous Cell Carcinoma of the Oral Cavity
Interventions: GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo; Drug
Lead sponsor: Gliknik Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
Interventions: MI-based HIV Risk Reduction; Other
Lead sponsor: Michele Staton; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Hazard, Kentucky

Conditions: Weight Loss
Interventions: High protein diet, Resistance Training (RT) Programs; Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 30 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: Moderate-Intensity Aerobic Training, High-Intensity Interval Training; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 30 Years to 85 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Newark, Delaware • Kansas City, Kansas • Cincinnati, Ohio

Conditions: Uveitis; Posterior, Disorder
Interventions: DE-109 44 ug, DE-109 440 ug, DE-109 880 ug; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 74
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 71 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Cesium 131; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills, Advance Directives, Natural Language Processing, Covid19
Interventions: VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:, Medical Record Review; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 65 Years and older
Enrollment: 42,019 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Lupus Nephritis
Interventions: Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 17
States / cities: La Palma, California • San Leandro, California • Torrance, California + 13 more

Conditions: Hemiparesis
Interventions: commercially available control algorithm, experimental control algorithm; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dyslipidemias, Pre-diabetes
Interventions: Placebo treatment, Plant derived phenolics; Other · Dietary Supplement
Lead sponsor: Brightseed; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Autistic Disorder
Interventions: citalopram hydrobromide, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Albany, New York • New York, New York

Conditions: Multiple Sclerosis
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Allergic Reaction
Interventions: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: High intensity endurance exercise, Stretching exercise, Virtual reality (VR)-based gaming; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: High Intensity Interval Exercise, Moderate Intensity Continuous Exercise, Control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 51 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Venothromboembolism
Interventions: Risk model-driven CDS; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 2,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions: PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle); Drug
Lead sponsor: PICO IV, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Canavan Disease
Interventions: AAV9 BBP-812; Biological
Lead sponsor: Aspa Therapeutics; Industry
Eligibility: Up to 30 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 4
States / cities: Oakland, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Oral Squamous Cell Carcinoma
Interventions: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable); Drug
Lead sponsor: Privo Technologies; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Duarte, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Asthma
Interventions: MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Budesonide inhalation suspension 0.5mg; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Violence
Interventions: Your Voice Your View; Behavioral
Lead sponsor: Lifespan; Other
Eligibility: Not listed
Enrollment: 7,910 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Preoperative Cognitive Therapy for Improving Health Outcomes After TKA in High-risk Catastrophizing Subjects

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Brief Intervention for Rural Women at High Risk for HIV/HCV

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

HIT-Stroke Trial 2

Study Assessing Double-masked Uveitis Treatment

Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Improving Myoelectric Prosthetic and Orthotic Limb Control

Dietary Supplementation on Body Fat Composition

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD

Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

A Study of 2 Doses of MAP0010 in Adult Asthmatics

Preventing Sexual Aggression Among High School Boys